Google
NERV — MINERVA NEUROSCIENCES INC (Healthcare >> Biotechnology)
NERV FAQ
What is NERV's ROE?
MINERVA NEUROSCIENCES INC reports a Return on Equity (ROE) of 163.41%.
What is NERV's dividend yield?
MINERVA NEUROSCIENCES INC offers a dividend yield of 0.00%.
What is NERV's Deepscope Quality Score?
Deepscope rates NERV's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NERV?
Deepscope's AI Timing Score for NERV is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NERV belong to?
MINERVA NEUROSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.96
Price
0.18
(3.77%)
Day Change
|
|
|---|
NERV, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.96 |
| PBV / Sector |
-0.88 / 4.63
|
| Earning Per Share | -9.16 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.73 M
GREAT
|
| Average 1W Daily Value |
0.55 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:04 |
| Symbol | NERV |
| Name | MINERVA NEUROSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 46.59 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 224.79 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1500 District Avenue, Burlington, MA, United States, 01803
Phone: 617 600 7373
Website: https://www.minervaneurosciences.com
Sector: Healthcare >> Biotechnology
Description: Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
